| Host |
Rabbit |
| Clone |
SP72 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
A synthetic peptide corresponding to C-terminus of human myeloperoxidase protein |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Zytomed Systems GmbH |
SP72 |
0.1 ml |
Concentrate |
RUO |
513-3720 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
1 ml |
Concentrate |
CE/IVD |
MOB551 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB551-01 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB551-05 |
-
|
| Host |
Mouse |
| Clone |
59A5 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Mouse IgG2b kappa |
| Immunogen |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM551 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR049 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP053 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP053-01 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP053-05 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
1 ml |
Concentrate |
CE/IVD |
MOB278 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.1 ml |
Concentrate |
CE/IVD |
MOB278-01 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.5 ml |
Concentrate |
CE/IVD |
MOB278-05 |
-
|
| Host |
Mouse |
| Clone |
5.2F |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Tonsil |
| Dilution |
- |
| Isotype |
Mouse IgG2a |
| Localization |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
6 ml |
Ready-to-use |
CE/IVD |
PDM120 |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
1 ml |
Concentrate |
CE/IVD |
Z2576RL |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Ready-to-use |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
RTU |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
7.0 ml |
Ready-to-use |
CE/IVD |
Z2576RP |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.5 ml |
Concentrate |
CE/IVD |
Z2576RS |
-
|
| Host |
Rabbit |
| Clone |
ZR262 |
| Format |
Concentrate |
| Method |
P |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.1 ml |
Concentrate |
CE/IVD |
Z2576RT |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
1 ml |
Concentrate |
CE/IVD |
MOB322 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
MOB322-01 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Method |
F, P, WB, IP, IF |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
MOB322-05 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Rhabdomyosarcoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
6 ml |
Ready-to-use |
CE/IVD |
PDM158 |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
1ml |
Concentrate |
CE/IVD |
Z2054ML |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
7 ml |
Ready-to-use |
CE/IVD |
Z2054MP |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
Z2054MS |
-
|
| Host |
Mouse |
| Clone |
F5D |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Recombinant protein containing rat myogenin aa 30-224 |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
Z2054MT |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
1.0 ml |
Concentrate |
CE/IVD |
Z2462ML |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
7 ml |
Ready-to-use |
CE/IVD |
Z2462MP |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.5 ml |
Concentrate |
CE/IVD |
Z2462MS |
-
|
| Host |
Mouse |
| Clone |
ZM149 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Rhabdomyosarcoma or Wilm's tumor. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Human myogenin recombinant protein |
| Localization |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.1 ml |
Concentrate |
CE/IVD |
Z2462MT |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
1 ml |
Concentrate |
CE/IVD |
MOB207 |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
0.1 ml |
Concentrate |
CE/IVD |
MOB207-01 |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Concentrate |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
1:25 - 1:50 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
0.5 ml |
Concentrate |
CE/IVD |
MOB207-05 |
-
|
| Host |
Mouse |
| Clone |
MY32 |
| Format |
Ready-to-use |
| Method |
F, P |
| Positive control |
Skeletal Muscle |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
6 ml |
Ready-to-use |
CE/IVD |
PDM085 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
1:100 - 1:500 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
1 ml |
Concentrate |
CE/IVD |
MOB467 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
1:100 - 1:500 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB467-01 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
1:100 - 1:500 |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB467-05 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Colon, appendix |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Immunogen |
Human uterus smooth muscle extract |
| Localization |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM175 |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
1ml |
Concentrate |
CE/IVD |
Z2229ML |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
- |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2229MP |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2229MS |
-
|
| Host |
Mouse |
| Clone |
SMMS-1 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Transitional cell carcinoma. |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1 /κ |
| Immunogen |
Crude human uterus extract |
| Localization |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2229MT |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Diva modified Citrate pH 6.2 |
| Positive control |
Lung adenocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3043A |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Diva modified Citrate pH 6.2 |
| Positive control |
Lung adenocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
1 ml |
Concentrate |
CE/IVD |
ACI3043C |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Diva modified Citrate pH 6.2 |
| Positive control |
Lung adenocarcinoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
6 ml |
Ready-to-use |
CE/IVD |
API3043AA |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
1 ml |
Concentrate |
CE/IVD |
MOB463 |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB463-01 |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB463-05 |
-
|
| Host |
Mouse |
| Clone |
KCG1.1 |
| Format |
Ready-to-use |
| Method |
F, P |
| Pretreatment |
Citrate |
| Positive control |
Lung Adenocarcinoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Localization |
Cytoplasm |
Napsin A
|
Diagnostic Biosystems |
KCG1.1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM154 |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
lung adenocarcinoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
Napsin A
|
Zytomed Systems GmbH |
BC15 |
6 ml |
Ready-to-use |
CE/IVD |
RBG059 |
-
|
| Host |
Rabbit |
| Clone |
BC15 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
lung adenocarcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Localization |
Cytoplasm |
Napsin A
|
Zytomed Systems GmbH |
BC15 |
0.5 ml |
Concentrate |
CE/IVD |
RBK059-05 |
-
|